Liver diseases are a major public health concern that affects millions of people each year. The only appropriate treatment option for severe liver diseases, liver transplantation, is hampered by high costs and a scarcity of donor livers.
Patients suffering from liver diseases now have new hope thanks to Stem Cell Therapy India. Cell-based therapy can successfully treat a wide range of life-threatening liver diseases, regardless of their etiologies, symptoms, or physiological functions, as three decades of clinical and preclinical research has shown. Mesenchymal stem cells (MSC) and primary hepatocytes are two of the most clinically derived cell sources for allogeneic or autologous transplantation.
Here are a few examples of MSC applications in various liver diseases:
Cirrhosis of the Liver
Liver fibrosis is a chronic condition caused by a variety of factors such as viral infection, medication side effects, alcoholism, and immunological disorders. Chronic liver injury causes excessive extracellular matrix (ECM) deposition via cycles of hepatocyte death, inflammation, and recurrent damage repair. Cirrhosis is the final stage of progressive fibrosis for which no effective treatment exists. MSCs can differentiate into hepatocyte-like cells and secrete immune-regulating factors. As a result, MSCs play a direct and indirect role in tissue repair.
Acute Liver Impairment (ALF)
Acute liver failure is defined by a loss of liver function that occurs suddenly — within days or weeks — in a person who has never had liver disease. The most common causes are the hepatitis virus or medications such as acetaminophen. Acute liver failure is less common than chronic liver failure, which develops over time. Numerous studies have demonstrated the role of MSCs in the treatment of ALF animal models. MSCs have been shown to reduce mortality, improve liver function, prevent hepatocyte apoptosis, and stimulate hepatocyte growth. Some research also suggests that Stem Cell Treatment India can help with ALF by regulating the immune system. Currently, the use of MSCs in ALF is limited to basic research. MSCs, on the other hand, have long been recognised for their ability to promote liver regeneration and reduce inflammation.
Cancer of the Liver
MSCs have been shown to have the ability to spread and integrate into tumour tissue. However, the use of multi-origin MSCs in the treatment of liver cancer is debatable. MSCs from various sources perform different functions in liver cancer, limiting their clinical application. MSCs may be useful for delivering medicines or anti-tumor viruses due to their tumour chemotaxis abilities, immunosuppressive capabilities, and low immunogenicity.
In conclusion, when combined with stem cells in the treatment of liver disease, stem cell therapy can improve liver function in the short term. Patients with end-stage liver disease may be able to wait a little longer for a liver transplant if they receive stem cell therapy. It can also serve as a bridge between advanced liver disease and liver transplantation. Recurrent stem cell therapy may be an excellent way to achieve long-term clinical outcomes. More controlled trials are needed to determine how stem cells function in liver disease.